New LSD-Derived Drug Shows Promise for Long-Term Anxiety Relief, Optimal Dose Identified
AI-Generated Summary
A new pharmaceutical version of LSD, MM120, has demonstrated significant efficacy in treating generalized anxiety disorder (GAD). A single 100mg dose was found to alleviate severe anxiety symptoms for up to 12 weeks in a clinical study. Published in JAMA, these findings suggest a potential paradigm shift in future anxiety treatments.
In a nutshell
This research represents a significant advancement in mental health treatment, potentially offering long-lasting, single-dose therapies for conditions like GAD. It also highlights the ongoing scientific re-evaluation of previously illicit substances for their therapeutic potential under rigorous medical scrutiny.
Source: Gloucestershire Live
